Open AccessMajor Adverse Cardiac Events in Patients With Hepatitis C Infection Treated With Bare‐Metal Versus Drug‐Eluting Stents
Author(s) -
Palaniswamy Chandrasekar,
Aronow Wilbert S.,
Sukhija Rishi,
Chugh Tarun,
Ramdeen Navi,
Kalapatapu Kumar,
Weiss Melvin B.,
Pucillo Anthony L.,
Monsen Craig E.
Publication year - 2010
Publication title -
clinical cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.263
H-Index - 72
eISSN - 1932-8737
pISSN - 0160-9289
DOI - 10.1002/clc.20764
Subject(s) - medicine , mace , percutaneous coronary intervention , myocardial infarction , cardiology , hepatitis c , drug eluting stent , stent , incidence (geometry) , surgery , hepatitis c virus , immunology , virus , physics , optics
Background There are no data comparing the long‐term outcome of bare‐metal stents (BMS) vs drug‐eluting stents (DES) in patients with hepatitis C virus (HCV) infection. Hypothesis In patients with HCV infection, the rate of major adverse cardiac events (MACE) would be less, and the mortality rates similar, in patients treated with DES than in patients treated with BMS. Methods The incidence of major adverse cardiac events (MACE) during long‐term follow‐up, including death, myocardial infarction, and target‐vessel revascularization, was investigated in HCV‐infected patients who also underwent percutaneous coronary intervention with bare‐metal or drug‐eluting stents. Results Of 78 patients studied, BMS were placed in 41 patients and DES stents in 37 patients. Stepwise Cox regression analyses were performed to identify significant independent risk factors for MACE. At 42 ± 11 − month follow‐up, MACE occurred in 9 of 41 patients (22%) in the BMS group (mean age 63 ± 11 years, 66% men) vs in 7 of 37 patients (19%) in the DES group (mean age 61 ± 9 years, 65% men). There was no significant difference in MACE in the BMS group vs the DES group. This persisted even after controlling for length of the stent, complexity of lesion, and other comorbidities. All‐cause mortality was not significantly different in the BMS group vs the DES group (7% vs 5%). Conclusions At long‐term follow‐up of HCV‐infected patients with stable liver function, the rates of MACE and of all‐cause mortality were similar in the BMS and DES groups. Copyright © 2010 Wiley Periodicals, Inc.